Sean D. Pokorney

Sean D. Pokorney

Auto-generated profile, based on publicly available information

Sean D. Pokorney

Division of Cardiology, Duke University Medical Center, Durham, NC 27710, USA; Department of Medicine, Duke Clinical Research Institute, Durham, NC 27710, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2022 in Circulation
Verified
Journal Article
Closed access
PDF file
SPSean D. Pokorney
Sean D. Pokorney
GCGlenn M. Chertow
Glenn M. Chertow
HAHussein R. Al-Khalidi
Hussein R. Al-Khalidi
DGDianne Gallup
Dianne Gallup
PDPat Dignacco
Pat Dignacco
OIon behalf of the RENAL-AF Investigators
on behalf of the RENAL-AF Investigators
Background: There are no randomized data evaluating the safety or efficacy of apixaban for stroke prevention in patients with end-stage kidney disease on hemodialysis and with atrial fibrillation (AF). Methods: The RENAL-AF trial (Renal Hemodialysis Patients Allocated Apixaban Versus Warfarin in Atrial Fibrillation) was a prospective, randomized, open-label, blinded-outcome evaluation (PROBE) of apixaban versus warfarin in patients receiving hemodialysis with AF and a CHA 2 DS 2 -VASc score ≥2. Patients were randomly assigned 1:1 to 5 mg of apixaban twice daily (2.5 mg twice daily for patients ≥80 years of age, weight ≤60 kg, or both) or dose-adjusted warfarin. The primary outcome was time to major or clinically relevant nonmajor bleeding. Secondary outcomes included stroke, mortality, and apixaban pharmacokinetics. Pharmacokinetic sampling was day 1, day 3, and month 1. Results: From January 2017 through January 2019, 154 patients were randomly assigned to apixaban (n=82) or warfarin (n=72). The trial stopped prematurely because of enrollment challenges. Time in therapeutic range (international normalized ratio, 2.0–3.0) for warfarin-treated patients was 44% (interquartile range, 23%–59%). The 1-year rates for major or clinically relevant nonmajor bleeding were 32% and 26% in apixaban and warfarin groups, respectively (hazard ratio, 1.20 [95% CI, 0.63–2.30]), whereas 1-year rates for stroke or systemic embolism were 3.0% and 3.3% in apixaban and warfarin groups, respectively. Death was the most common major event in the apixaban (21 patients [26%]) and warfarin (13 patients [18%]) arms. The pharmacokinetic substudy enrolled the target 50 patients. Median steady-state 12-hour area under the curve was 2475 ng/mL×h (10th to 90th percentiles, 1342–3285) for 5 mg of apixaban twice daily and 1269 ng/mL×h (10th to 90th percentiles, 615–1946) for 2.5 mg of apixaban twice daily. There was substantial overlap between minimum apixaban blood concentration, 12-hour area under the curve, and maximum apixaban blood concentration for patients with and without a major or clinically relevant nonmajor bleeding event. Conclusions: There was inadequate power to draw any conclusion regarding rates of major or clinically relevant nonmajor bleeding comparing apixaban and warfarin in patients with AF and end-stage kidney disease on hemodialysis. Clinically relevant bleeding events were ≈10-fold more frequent than stroke or systemic embolism among this population on anticoagulation, highlighting the need for future randomized studies evaluating the risks versus benefits of anticoagulation among patients with AF and end-stage kidney disease on hemodialysis. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02942407.

6 June 2023 in Circulation
Verified
Journal Article
Closed access
JHJosephine Harrington
Josephine Harrington
ACAnthony P. Carnicelli
Anthony P. Carnicelli
KHKaiyuan Hua
Kaiyuan Hua
LWLars Wallentin
Lars Wallentin
MPManesh R. Patel
Manesh R. Patel
CGChristopher B. Granger
Christopher B. Granger
Background: There is uncertainty surrounding the use of direct oral anticoagulants (DOACs) in patients with kidney dysfunction. Methods: Using the COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) database (data from RE-LY [Randomized Evaluation of Long-term Anticoagulation Therapy], ROCKET AF [Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation], ARISTOTLE [Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation], and ENGAGE AF-TIMI 48 [Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48]), we performed an individual patient-level network meta-analysis to evaluate the safety and efficacy of DOACs versus warfarin across continuous creatinine clearance (CrCl). A multivariable Cox model including treatment-by-CrCl interaction with random effects was fitted to estimate hazard ratios for paired treatment strategies (standard-dose DOAC, lower-dose DOAC, and warfarin). Outcomes included stroke and systemic embolism (S/SE), major bleeding, intracranial hemorrhage (ICH), and death. Results: Among 71 683 patients (mean age, 70.6±9.4 years; 37.3% female; median follow-up, 23.1 months), the mean CrCl was 75.5±30.5 mL/min. The incidence of S/SE, major bleeding, ICH, and death increased significantly with worsening kidney function. Across continuous CrCl values down to 25 mL/min, the hazard of major bleeding did not change for patients randomized to standard-dose DOACs compared with those randomized to warfarin ( P interaction =0.61). Compared with warfarin, standard-dose DOAC use resulted in a significantly lower hazard of ICH at CrCl values <122 mL/min, with a trend for increased safety with DOAC as CrCl decreased (6.2% decrease in hazard ratio per 10-mL/min decrease in CrCl; P interaction =0.08). Compared with warfarin, standard-dose DOAC use resulted in a significantly lower hazard of S/SE with CrCl <87 mL/min, with a significant treatment-by-CrCl effect (4.8% decrease in hazard ratio per 10-mL/min decrease in CrCl; P interaction =0.01). The hazard of death was significantly lower with standard-dose DOACs for patients with CrCl <77 mL/min, with a trend toward increasing benefit with lower CrCl (2.1% decrease in hazard ratio per 10-mL/min decrease in CrCl; P interaction =0.08). Use of lower-dose rather than standard-dose DOACs was not associated with a significant difference in incident bleeding or ICH in patients with reduced kidney function but was associated with a higher incidence4 of death and S/SE. Conclusions: Standard-dose DOACs are safer and more effective than warfarin down to a CrCl of at least 25 mL/min. Lower-dose DOACs do not significantly lower the incidence of bleeding or ICH compared with standard-dose DOACs but are associated with a higher incidence of S/SE and death. These findings support the use of standard-dose DOACs over warfarin in patients with kidney dysfunction.

10 October 2017 in Circulation
Verified
Journal Article
Closed access
PDF file
SPSean D. Pokorney
Sean D. Pokorney
XMXiaojuan Mi
Xiaojuan Mi
RLRobert K. Lewis
Robert K. Lewis
MGMelissa Greiner
Melissa Greiner
LELaurence M. Epstein
Laurence M. Epstein
JPJonathan P. Piccini
Jonathan P. Piccini
Background: Lead management is an increasingly important aspect of care in patients with cardiac implantable electronic devices; however, relatively little is known about long-term outcomes after capping and abandoning leads. Methods: Using the 5% Medicare sample, we identified patients with de novo cardiac implantable electronic device implantations between January 1, 2000, and December 31, 2013, and with a subsequent lead addition or extraction ≥12 months after the de novo implantation. Patients who underwent extraction for infection were excluded. Using multivariable Cox proportional hazards models, we compared cumulative incidence of all-cause mortality, device-related infection, device revision, and lead extraction at 1 and 5 years for the extraction versus the cap and abandon group. Results: Among 6859 patients, 1113 (16.2%) underwent extraction, whereas 5746 (83.8%) underwent capping and abandonment. Extraction patients tended to be younger (median, 78 versus 79 years; P <0.0001), were less likely to be male (65% versus 68%; P =0.05), and had shorter lead dwell time (median, 3.0 versus 4.0 years; P <0.0001) and fewer comorbidities. Over a median follow-up of 2.4 years (25th, 75th percentiles, 1.0, 4.3 years), the overall 1-year and 5-year cumulative incidence of mortality was 13.5% (95% confidence interval [CI], 12.7–14.4) and 54.3% (95% CI, 52.8–55.8), respectively. Extraction was associated with a lower risk of device infection at 5 years relative to capping (adjusted hazard ratio, 0.78; 95% CI, 0.62–0.97; P =0.027). There was no association between extraction and mortality, lead revision, or lead extraction at 5 years. Conclusions: Elective lead extraction for noninfectious indications had similar long-term survival to that for capping and abandoning leads in a Medicare population. However, extraction was associated with lower risk of device infections at 5 years.

23 June 2015 in JAMA
Verified
Journal Article
Open access
PDF file
SPSean D. Pokorney
Sean D. Pokorney
AMAmy L. Miller
Amy L. Miller
ACAnita Y. Chen
Anita Y. Chen
LTLaine Thomas
Laine Thomas
GFGregg C. Fonarow
Gregg C. Fonarow
TWTracy Y. Wang
Tracy Y. Wang
Quiz Ref ID More than 350 000 people experience sudden cardiac death in the United States annually.1 Randomized clinical trials established the benefit of primary prevention implantable cardioverter-defibrillators (ICDs) among patients with low ejection fraction (EF).2,3 Timing of ICD implantation is critical as studies have not found a benefit to ICD implantation early after myocardial infarction (MI).4,5 Guidelines recommend primary prevention ICD implantation in patients with an EF of 35% or lower despite being treated with optimal medical therapy for at least 40 days after an MI.6

1 January 2012 in Journal of Cardiovascular Magnetic Resonance
Verified
Journal Article
Open access
PDF file
SPSean D Pokorney
Sean D Pokorney
JRJose Rodríguez-Palomares
Jose Rodríguez-Palomares
JOJosé T Ortiz
José T Ortiz
DLDaniel C Lee
Daniel C Lee
RBRobert O Bonow
Robert O Bonow
EWEdwin Wu
Edwin Wu
The role of infarct size on left ventricular (LV) remodeling in heart failure after an acute ST-segment elevation myocardial infarction (STEMI) is well recognized. Infarct size, as determined by cardiovascular magnetic resonance (CMR), decreases over time. The amount, rate, and duration of infarct healing are unknown.

20 December 2017 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
SPSean D. Pokorney
Sean D. Pokorney
SASana M. Al-Khatib
Sana M. Al-Khatib
JSJie-Lena Sun
Jie-Lena Sun
PSPhillip Schulte
Phillip Schulte
COChristopher M. O'COnnor
Christopher M. O'COnnor
RMRobert J. Mentz
Robert J. Mentz
Aims The incidence of and factors associated with sudden cardiac death (SCD) early after an acute heart failure (HF) hospital admission have not been well defined. Methods and results We assessed SCD and ventricular arrhythmias in the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND‐HF) trial, which included patients with acute HF with reduced or preserved ejection fraction. SCD, resuscitated SCD (RSCD), and sustained ventricular tachycardia/ventricular fibrillation (VT/VF) were adjudicated from randomization through 30 days and were combined into a composite endpoint. Baseline characteristics associated with this composite were determined by logistic regression. RSCD and VT/VF were included as time‐dependent variables in a Cox model evaluating the association of these variables with 180‐day all‐cause mortality. Among 7011 patients, the 30‐day all‐cause mortality rate was 3.8%; SCD accounted for 17% of these deaths. The 30‐day composite event rate was 1.8% (n = 121). Ten patients had more than one event with 30‐day Kaplan–Meier event rates of 0.6% for SCD [95% confidence interval (CI) 0.5%–0.9%, n = 43], 0.4% for RSCD (95% CI 0.2%–0.5%, n = 24), and 0.9% for VT/VF (95% CI 0.7%–1.2%, n = 64). In the multivariable model, chronic obstructive pulmonary disease, history of VT, male sex, and longer QRS duration were associated with SCD, RSCD, or VT/VF. A RSCD or VT/VF event was associated with higher 180‐day mortality (adjusted hazard ratio 6.6, 95% CI 4.8–9.1, P < 0.0001). Conclusions Approximately 2% of patients admitted for acute HF experienced SCD, RSCD, or VT/VF within 30 days of admission, and SCD accounted for 17% of all deaths within 30 days.